


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                ----------------

                                    FORM 8-K

                                ----------------

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) DECEMBER 20, 2004

                                ----------------

                               NOVADEL PHARMA INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                ----------------

         DELAWARE                       001-32177              22-2407152
 (STATE OR OTHER JURISDICTION     (COMMISSION FILE NO.)     (I.R.S. EMPLOYER
       OF INCORPORATION)                                    IDENTIFICATION NO.)

                              25 MINNEAKONING ROAD
                          FLEMINGTON, NEW JERSEY 08822
               (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

                                 (908) 782-3431
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

                                       N/A
          (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c)) 3

================================================================================

<PAGE>
                                                                               2


ITEM  1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

The information set forth under Item 5.02,  "Departure of Directors or Principal
Officers;  Election  of  Directors;   Appointment  of  Principal  Officers",  is
incorporated herein by reference.

ITEM  5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
      APPOINTMENT OF PRINCIPAL OFFICERS.

On December 20, 2004,  Michael  E.B.  Spicer  joined  NovaDel  Pharma Inc.  (the
"Company"), as the Company's Chief Financial Officer. The Company and Mr. Spicer
entered  into a definitive  employment  agreement,  the material  terms of which
include a three  year term of  employment  and an annual  base  salary  equal to
$235,000,  subject to  periodic  review by the  Company  and a cash bonus at the
completion of each full year of Mr. Spicer's  employment by the Company equal to
30% of his base salary,  payable  only upon  successful  achievement  of certain
performance  milestones,  which  milestones  shall be defined and  enumerated by
mutual  agreement  between  Mr.  Spicer and the  Company's  President  and Chief
Executive  Officer.  In addition,  the Company  issued to Mr. Spicer  options to
purchase a total of 100,000  shares of common  stock of the Company  pursuant to
the terms and  conditions  of the Company's  1998 Stock Option Plan.  Such stock
options vest as follows: 33,333 of the options vest on December 20, 2005; 33,333
of the options  vest on December  20,  2006;  and 33,334 of the options  vest on
December 20, 2007.  The Company issued a press release  announcing Mr.  Spicer's
appointment  on December  22,  2004.  The full text of the press  release is set
forth in Exhibit 99.1 hereto.

This description of the material terms of Mr. Spicer's  employment  agreement is
qualified in its entirety by reference to the employment  agreement  dated as of
December 20, 2004,  which is attached  hereto as Exhibit 10.35 and  incorporated
herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

      (c)   Exhibits.

      10.35 Employment Agreement dated as of December 20, 2004, by and between
            NovaDel Pharma Inc., and Michael E.B. Spicer.

      99.1  Press release dated December 22, 2004, titled "NovaDel Names Michael
            E.B. Spicer Chief Financial Officer."


<PAGE>
                                                                               3

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                       NOVADEL PHARMA INC.


                                       By:  /s/ Jean W. Frydman
                                           ----------------------
                                       Name:  Jean W. Frydman
                                       Title: Vice President and General Counsel

Date: December 23, 2004


